Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bleomycin
Drug ID BADD_D00280
Description A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Indications and Usage For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
Marketing Status Prescription; Discontinued
ATC Code L01DC01
DrugBank ID DB00290
KEGG ID D07535
MeSH ID D001761
PubChem ID 5460769
TTD Drug ID D06UVD
NDC Product Code 61703-323; 0143-9240; 0703-3155; 16714-908; 0409-0332; 61703-332; 16714-886; 0143-9241; 70121-1567; 0703-3154; 0409-0323; 69097-364
Synonyms Bleomycin | Bleomycins | BLEO-cell | BLEO cell | BLEOcell | Bleolem | Bléomycine Bellon | Bellon, Bléomycine | Bleomycin A2 | Bleomycin A(2) | Bleomycin B2 | Bleomycin B(2) | Bleomycin Sulfate | Sulfate, Bleomycin | Bleomycinum Mack | Mack, Bleomycinum | Blenoxane | Blanoxan | Bleomicina
Chemical Information
Molecular Formula C55H84N17O21S3+
CAS Registry Number 11056-06-7
SMILES CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O) OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6 =NC(=CS6)C(=O)NCCC[S+](C)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pneumonia22.07.01.003; 11.01.09.0030.001598%Not Available
Pneumonitis22.01.01.0060.001865%
Pneumothorax22.05.02.0030.000208%
Pre-eclampsia24.08.07.002; 20.01.08.002; 18.02.03.0020.000533%Not Available
Premature baby18.04.02.0010.001598%Not Available
Premature delivery18.07.01.0060.000533%
Protrusion tongue17.02.05.037; 07.14.02.0020.000139%Not Available
Pruritus23.03.12.001--
Pulmonary embolism22.06.02.001; 24.01.06.0010.003996%Not Available
Pulmonary fibrosis22.01.02.0060.000556%
Pyrexia08.05.02.0030.002131%
Radiation pneumonitis22.01.04.001; 12.05.02.002--Not Available
Rales22.02.04.004--Not Available
Rash23.03.13.001--Not Available
Raynaud's phenomenon24.04.03.0030.000533%Not Available
Renal failure20.01.03.0050.000139%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.000533%Not Available
Respiratory distress22.02.01.0120.000139%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000903%
Scleroderma23.03.02.005; 15.06.01.002; 10.04.07.0010.000486%Not Available
Second primary malignancy16.16.01.0140.000139%
Sepsis11.01.11.0030.000417%
Septic shock24.06.02.011; 11.01.11.0040.000208%Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin hypertrophy23.01.04.002--Not Available
Skin striae23.01.05.002--Not Available
Splenic infarction24.04.07.003; 01.09.02.0040.000533%Not Available
Stomatitis07.05.06.0050.000799%
Tachycardia02.03.02.0070.000533%Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages